Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical characteristics of 121 patients with systemic sclerosis (SSc) according to the presence or absence of anti-centromere-associated protein antibodies (ACA)

From: Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

Variable All patients ACA-positive (n= 75) ACA-negative (n= 46) P-value
Female, n (%) 113 (93.4) 71 (94.7) 42 (91.3) 0.470a
Age at diagnosis, years 38.8 (14.3) 39.3 (13.7) 37.8 (15.5) 0.530b
Disease duration, years 17.1 (10.3) 18.4 (10.6) 14.7 (9.4) 0.050b
Limited disease, n (%) 94 (77.7) 70 (93.3) 24 (52.2) <0.0001 a
mRss 5.70 (7.00) 3.90 (6.40) 9.00 (7.10) <0.0001 b
FVC, % of predicted 105.60 (20.20) 107.40 (19.10) 84.30 (22.20) 0.014b
DLCO, % of predicted 73.10 (23.80) 76.60 (25.00) 64.10 (17.80) 0.017b
sPAP, mm Hg 28.10 (10.60) 27.70 (11.60) 28.80 (8.80) 0.058b
ILD, n (%) 24 (27.6) 13 (18.0) 36 (78.6) <0.0001a
PAH, n (%) 16 (13.2) 8 (10.7) 8 (17.4) 0.289a
Disease severity scale     
   Total score 5.89 (3.46) 5.17 (2.80) 7.20 (4.12) 0.009b
   General 0.50 (0.80) 0.44 (0.70) 0.60 (0.93) 0.484b
   Peripheral vascular 1.52 (0.71) 1.46 (0.68) 1.61 (0.76) 0.212b
   Skin 0.83 (0.65) 0.66 (0.64) 1.14 (0.56) <0.0001b
   Joint/tendon 0.47 (1.00) 0.26 (0.64) 0.85 (1.35) 0.012b
   Muscle 0.16 (0.50) 0.10 (0.42) 0.26 (0.62) 0.090b
   Gastrointestinal tract 0.83 (0.70) 0.77 (0.66) 0.94 (0.72) 0.200b
   Lung 1.34 (1.11) 1.22 (1.18) 1.54 (0.96) 0.111b
   Heart 0.24 (0.50) 0.24 (0.42) 0.25 (0.63) 0.514b
   Kidney 0.05 (0.41) 0.0 (0.0) 0.14 (0.68) 0.058b
Disease activity index 1.52 (1.68) 1.26 (1.31) 1.98 (2.14) 0.128b
  1. Values are presented as mean (SD) unless otherwise indicated. aChi-squared test; bMann-Whitney U-test. mRss, modified Rodnan skin score; FVC, forced vital capacity; DLCO, diffusing lung capacity for carbon monoxide; sPAP, systolic pulmonary arterial pressure; PAH, pulmonary arterial hypertension (sPAP >35 mm Hg); ILD, interstitial lung disease.